Ulrika S H Simonsson (Ulrika Sh Simonsson)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 24

Top Topics

Machine Learning

Respiratory Tract

Top Venues

Clinical pharmacology and therapeutics

JMIR mHealth and uHealth

This page only lists publications with an associated author ORCID identifier.

Publications

Alan Faraj, Joakim Nyberg, Grant E Blouse, Tom Knudsen, Ulrika S H Simonsson
Subcutaneous Marzeptacog Alfa (Activated) for On-Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors. Clinical pharmacology and therapeutics (2024)
Laurynas Mockeliunas, Rob C van Wijk, Caryn M Upton, Jonathan Peter, Andreas H Diacon, Ulrika S H Simonsson
Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus Pandemic. Vaccines 12 (3) (2024)
Alan Faraj, Joakim Nyberg, Grant E Blouse, Tom Knudsen, Ulrika S H Simonsson
Subcutaneous Marzeptacog Alfa (Activated) for On-Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors. Clinical pharmacology and therapeutics 115 (3) (2024)
Laurynas Mockeliunas, Rob C van Wijk, Caryn M Upton, Jonathan Peter, Andreas H Diacon, Ulrika S H Simonsson
Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus Pandemic. Vaccines 12 (3) (2024)
Alan Faraj, Joakim Nyberg, Grant E Blouse, Tom Knudsen, Ulrika S H Simonsson
Subcutaneous marzeptacog alfa (activated) for on-demand treatment of bleeding events in subjects with haemophilia A or B with inhibitors. Clinical pharmacology and therapeutics (2024)
Alan Faraj, Joakim Nyberg, Grant E Blouse, Tom Knudsen, Ulrika S H Simonsson
Subcutaneous Marzeptacog Alfa (Activated) for On-Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors. Clinical pharmacology and therapeutics 115 (3) (2024)
Alan Faraj, Joakim Nyberg, Grant E Blouse, Tom Knudsen, Ulrika S H Simonsson
Subcutaneous Marzeptacog Alfa (Activated) for On-Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors. Clinical pharmacology and therapeutics 115 (3) (2024)
Laurynas Mockeliunas, Rob C van Wijk, Caryn M Upton, Jonathan Peter, Andreas H Diacon, Ulrika S H Simonsson
Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus Pandemic. Vaccines 12 (3) (2024)
Lina Keutzer, Laurynas Mockeliunas, Marieke G G Sturkenboom, Mathieu S Bolhuis, Onno W Akkerman, Ulrika S H Simonsson
Derivation and Clinical Utility of Safety Targets for Linezolid-Related Adverse Events in Drug-Resistant Tuberculosis Treatment. Pharmaceuticals (Basel, Switzerland) 16 (11) (2023)
Alan Faraj, Natacha Le Moan, Eduard Gorina, Grant E Blouse, Tom Knudsen, Ulrika S H Simonsson
Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients. Advances in therapy (2023)
Rob Christiaan van Wijk, Laurynas Mockeliunas, Gerben van den Hoogen, Caryn M Upton, Andreas H Diacon, Ulrika S H Simonsson
Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19. Scientific reports 13 (1) (2023)
Veronique R de Jager, Nikhil Gupte, Silvia Nunes, Grace L Barnes, Rob Christiaan van Wijk, Joni Mostert, Susan E Dorman, Ahmed A Abulfathi, Caryn M Upton, Alan Faraj, Eric L Nuermberger, Gyanu Lamichhane, Elin M Svenson, Ulrika S H Simonsson, Andreas H Diacon, Kelly E Dooley
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial. American journal of respiratory and critical care medicine 205 (10) (2022)
Laurynas Mockeliunas, Lina Keutzer, Marieke G G Sturkenboom, Mathieu S Bolhuis, Lotte M G Hulskotte, Onno W Akkerman, Ulrika S H Simonsson
Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis. Pharmaceutics 14 (4) (2022)
Lina Keutzer, Huifang You, Ali Farnoud, Joakim Nyberg, Sebastian G Wicha, Gareth Maher-Edwards, Georgios Vlasakakis, Gita Khalili Moghaddam, Elin M Svensson, Michael Patrick Menden, Ulrika S H Simonsson, null On Behalf Of The Unite Tb Consortium
Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin. Pharmaceutics 14 (8) (2022)
Rob Christiaan van Wijk, Ulrika S H Simonsson
Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application. CPT: pharmacometrics & systems pharmacology 11 (8) (2022)
Alan Faraj, Tom Knudsen, Shraddha Desai, Linda Neuman, Grant E Blouse, Ulrika S H Simonsson
Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug. CPT: pharmacometrics & systems pharmacology (2022)
Lina Davies Forsman, Katarina Niward, Johanna Kuhlin, Xubin Zheng, Rongrong Zheng, Ran Ke, Chao Hong, Jim Werngren, Jakob Paues, Ulrika S H Simonsson, Erik Eliasson, Sven Hoffner, Biao Xu, Jan-Willem Alffenaar, Thomas Schön, Yi Hu, Judith Bruchfeld
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China. The European respiratory journal 57 (3) (2021)
Rob Christiaan van Wijk, Wanbin Hu, Sharka M Dijkema, Dirk-Jan van den Berg, Jeremy Liu, Rida Bahi, Fons J Verbeek, Ulrika S H Simonsson, Herman P Spaink, Piet H van der Graaf, Elke H J Krekels
Anti-tuberculosis effect of isoniazid scales accurately from zebrafish to humans. British journal of pharmacology 177 (24) (2020)
Oskar Clewe, Alan Faraj, Yanmin Hu, Anthony R M Coates, Ulrika S H Simonsson
A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosis. Journal of pharmacokinetics and pharmacodynamics 47 (5) (2020)
Ulrika S H Simonsson, Ulrika S H Simonsson
Medical Device Apps: An Introduction to Regulatory Affairs for Developers. JMIR mHealth and uHealth 8 (6) (2020)
Ulrika S H Simonsson, Sebastian Georg Wicha, Ulrika S H Simonsson
Mobile Health Apps for Improvement of Tuberculosis Treatment: Descriptive Review. JMIR mHealth and uHealth 8 (4) (2020)
Neeraj Gupta, Dean Bottino, Ulrika S H Simonsson, Cynthia J Musante, Tjerk Bueters, Theodore R Rieger, Sreeraj Macha, Marylore Chenel, Craig Fancourt, Jitendra Kanodia, Satyaprakash Nayak
Transforming Translation Through Quantitative Pharmacology for High-Impact Decision Making in Drug Discovery and Development. Clinical pharmacology and therapeutics 107 (6) (2019)
Robin J Svensson, Katarina Niward, Lina Davies Forsman, Judith Bruchfeld, Jakob Paues, Erik Eliasson, Thomas Schön, Ulrika S H Simonsson
Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis. British journal of clinical pharmacology 85 (10) (2019)
Chunli Chen, Sebastian G Wicha, Rikard Nordgren, Ulrika S H Simonsson
Comparisons of Analysis Methods for Assessment of Pharmacodynamic Interactions Including Design Recommendations. The AAPS journal 20 (4) (2018)